IP Verse

Pharmaceutical Composition Containing Rifaximin Alpha & Delta - EP3434265B1

PatentPatent Analysis

EP3434265

SANDOZ
Application Number
EP18193241A
Filing Date
Mar 22, 2017
Status
Revoked
May 24, 2024
Grant Date
Jul 7, 2021
External Links
Slate, Register, Google Patents
Similar Patents facing opposition
EP3373914B2
EP3536311B1
EP3390358B1

Bibliography

The patent EP3434265B1 was granted to Sandoz on Jul 7, 2021 following the initial filing on Mar 22, 2017 under the application number EP18193241A . The current legal status of the patent is Revoked.

AI Generated Summary New

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

TEVA PHARMACEUTICALSApr 7, 2022ADMISSIBLE
ALFRED E TIEFENBACHERApr 6, 2022ADMISSIBLE
ALFASIGMAMar 21, 2022ADMISSIBLE

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.

  • Date

    Description

  • Get instant alerts for new documents